Rigel Pharmaceuticals, Inc.
HealthcareNASDAQ:RIGL · NASDAQ Global Select
+$0.77 today
Vol 0.24M · Avg 0.37M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$299.8M of revenue converted into $364.2M of net income for the selected period. Gross margin is 93.1% and net margin is 124.4%, showing how much revenue survives after costs and taxes. EPS is $18.72, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M +64.1% | $179.3M +53.4% | $116.9M -2.8% | $120.2M -19.4% | $149.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $19.6M +5.2% | $18.6M +162.3% | $7.1M +306.5% | $1.7M +61.5% | $1.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $274.7M +71.0% | $160.6M +46.3% | $109.8M -7.4% | $118.5M -20.0% | $148.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 93.3% +3.7pp | 89.6% -4.3pp | 93.9% -4.6pp | 98.5% -0.7pp | 99.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $33.3M +42.4% | $23.4M -4.7% | $24.5M -59.3% | $60.3M -7.6% | $65.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $115.9M +2.5% | $113.1M +6.9% | $105.7M -6.0% | $112.5M +22.4% | $91.9M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $149.2M +9.3% | $136.4M +4.7% | $130.3M -25.2% | $174.0M +8.3% | $160.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.4M +8.4% | $2.2M +80.0% | $1.2M +24.0% | $998.0K -14.1% | $1.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | $131.6M +361.4% | $28.5M +267.9% | -$17.0M +68.5% | -$53.9M -377.3% | -$11.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 44.7% +28.8pp | 15.9% +30.4pp | -14.5% +30.3pp | -44.8% -37.2pp | -7.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $125.5M +418.6% | $24.2M +218.1% | -$20.5M +63.1% | -$55.5M -344.5% | -$12.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 42.6% +29.1pp | 13.5% +31.0pp | -17.5% +28.7pp | -46.2% -37.8pp | -8.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.7M +76.0% | $2.1M -7.9% | $2.3M +232.2% | $684.0K +1355.3% | $47.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.3M -7.6% | $7.9M +15.2% | $6.9M +85.4% | $3.7M -23.7% | $4.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.6M +37.5% | -$5.8M -26.7% | -$4.6M -52.2% | -$3.0M +37.2% | -$4.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $121.8M +563.3% | $18.4M +173.2% | -$25.1M +57.2% | -$58.6M -238.4% | -$17.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 41.4% +31.2pp | 10.2% +31.7pp | -21.5% +27.2pp | -48.7% -37.1pp | -11.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$245.2M -27931.7% | $881.0K | $0 | $0 -100.0% | $605.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $367.0M +1999.1% | $17.5M +169.7% | -$25.1M +57.2% | -$58.6M -227.0% | -$17.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 124.7% +115.0pp | 9.8% +31.2pp | -21.5% +27.2pp | -48.7% -36.7pp | -12.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $20 +1960.6% | $1 +168.7% | -$1 +57.6% | -$3 -209.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $19 +1867.7% | $1 +168.7% | -$1 +57.6% | -$3 -209.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $18.0M +2.3% | $17.6M +1.0% | $17.4M +0.9% | $17.2M +1.1% | $17.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $18.8M +6.5% | $17.7M +1.6% | $17.4M +0.9% | $17.2M +1.1% | $17.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Gossamer Bio, Inc.
GOSS
$38.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does RIGL generate?
Rigel Pharmaceuticals, Inc. (RIGL) reported $294.28M of revenue in fiscal 2025.
Is RIGL profitable?
Rigel Pharmaceuticals, Inc. (RIGL) reported $367.02M of net income, with a net margin of 124.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.